Delivery Order SPE2DB25D3018-SPE2DB25FUXYP
Award Date 7/11/25
Potential Completion Date 7/14/25
Potential Value $13K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order valued at $6,819.43 to AmerisourceBergen Drug Corp for the supply of DUPIXENT 200 MG/1.14 ML pen injectors on August 6, 2025, with completion expected by August 7, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. DUPIXENT (dupilumab) is a prescription biologic medication used to treat various...
- The Defense Logistics Agency awarded a $11,900.31 firm fixed price delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML pen injectors (2 ML) on July 2, 2025, with an ultimate completion date of July 3, 2025. This non-set-aside competitive award was performed at the contractor's corporate office location in Conshohocken, Pennsylvania. DUPIXENT (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis, asthma, and other allergic conditions, and its...
- The Defense Logistics Agency awarded a delivery order valued at $14,097.56 to AmerisourceBergen Drug Corp for the supply of DUPIXENT 300 mg/2 ml pen injectors on August 14, 2025, with an ultimate completion date of August 15, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. DUPIXENT (dupilumab) is a biologic immunosuppressant medication used to treat...
- The Defense Logistics Agency awarded a delivery order valued at $4,697.47 to AmerisourceBergen Drug Corp for the supply of DUPIXENT 300 MG/2 ML pen injectors on August 26, 2025, with an ultimate completion date of August 27, 2025. This firm fixed-price delivery order was competitively awarded without set-aside provisions and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. DUPIXENT (dupilumab) is a prescription biologic medication used to treat...
- The Defense Logistics Agency awarded a $39,444.01 firm fixed-price delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML pens on September 8, 2025, with an ultimate completion date of September 9, 2025. DUPIXENT (dupilumab) is a biologic medication used to treat conditions including atopic dermatitis, asthma, and chronic rhinosinusitis. This delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a $4,929.52 delivery order to AmerisourceBergen Drug Corp for DUPIXENT (dupilumab) 300 mg/2 mL pen injections on June 18, 2025, with an ultimate completion date of June 20, 2025. This non-competitive, firm fixed-price delivery order represents a continuation of pharmaceutical supply under AmerisourceBergen's existing contract vehicle with DLA. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a $24,542.35 delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of DUPIXENT 300 mg/2 mL pens (2 mL units). This is a firm fixed-price, non-set-aside contract with a completion date of July 23, 2025, and performance at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. DUPIXENT (dupilumab) is a biologic immunosuppressant used to treat moderate-to-severe atopic dermatitis, eosinophilic esophagitis, and other allergic...
- The Defense Logistics Agency awarded a delivery order valued at $12,879.52 to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML pen auto-injectors on August 8, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a $6,995.86 delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of DUPIXENT 300 MG/2 ML pen injectors (2 ML). This is a firm fixed price, non-set-aside contract with an ultimate completion date of September 19, 2025, and performance to be executed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $30,341.52 firm fixed-price delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 mL pen injectors on June 2, 2025, with an ultimate completion date of June 3, 2025. This non-set-aside award was competitively procured and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. DUPIXENT (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis, eosinophilic esophagitis, and...